Magstim, the pioneer of a revolutionary non-invasive treatment for depression, has announced that its latest TMS therapy product, the Horizon Performance, has achieved CE mark regulatory approval and 510(k) clearance from the FDA.
Morrisville, NC, October 17, 2017 — Magstim, a pioneer in the study and development of Transcranial Magnetic Stimulation (TMS), has received a contract from the Veterans Administration to help treat Major Depressive Disorder (MDD) in Veterans who have failed to achieve satisfactory improvement from prior antidepressant medication.
Magstim Group, Inc., the pioneer in trans-cranial magnetic stimulation and intraoperative nerve monitoring, today announced that it has appointed Lothar Krinke, Ph.D., as Chief Executive Officer effective immediately. Dr. Krinke will serve on the Board of Directors of Magstim. He will be responsible for Magstim and Technomed.
Effective, non-invasive & optimized for patient comfort.
Magstim® TMS Therapy provides higher performance, enhanced support and a higher ROI;
resulting in reduced costs and increased revenue for your TMS machine.
